Comparative Pharmacology
Head-to-head clinical analysis: MELFIAT versus OBESTIN 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELFIAT versus OBESTIN 30.
MELFIAT vs OBESTIN-30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melfiat is a sympathomimetic amine that acts as an anorectic agent. Its mechanism of action involves stimulating the release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to suppression of appetite.
ObesTin-30 is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake, increasing serotonin levels in the synaptic cleft, which modulates appetite and mood.
1 to 2 tablets (75 to 150 mg mazindol) orally once daily with breakfast.
30 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; half-life may be prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (70-80% as unchanged drug and metabolites), with ~20% eliminated via bile into feces.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose; fecal elimination via biliary excretion accounts for approximately 30%, with the remainder as metabolites.
Category C
Category C
Anorexiant
Anorexiant